The global stroke market is experiencing significant growth, driven by the increasing prevalence of stroke globally, advancements in stroke diagnostics, and improvements in treatment options. Stroke remains one of the leading causes of death and disability worldwide, prompting the development of new therapies, medical devices, and rehabilitation techniques. The rising aging population, along with lifestyle factors such as high blood pressure, diabetes, and unhealthy diets, are contributing to an increased incidence of stroke. In addition, innovations in imaging technologies, such as MRI and CT scans, are enabling quicker and more accurate diagnosis, facilitating faster interventions. Furthermore, the growing adoption of telemedicine and advancements in post-stroke rehabilitation, including robotic therapy and artificial intelligence-based solutions, are enhancing recovery and patient outcomes.
The Global Stroke Market size was valued at USD 32.57 billion in 2023 and is projected to reach USD 58.09 billion by 2031, with a CAGR of 7.50% during the forecast period of 2024 to 2031.
To know more, visit https://www.databridgemarketresearch.com/reports/global-stroke-market
Below are the Top Stroke Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Bristol-Myers Squibb Company
|
Bristol-Myers Squibb has a strong presence in the stroke market with medications targeting thrombotic events, particularly anticoagulants and antiplatelet agents. BMS is committed to advancing treatments that help improve the outcomes for stroke patients and reduce the risk of recurrence.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In March 2023, Bristol Myers Squibb in collaboration with Janssen Pharmaceuticals, Inc. (a Johnson & Johnson company), announced the launch of the Phase 3 Librexia program to evaluate milvexian, an investigational oral factor XIa (FXIa) inhibitor for antithrombotic therapy. The Librexia program is the most extensive FXIa development initiative to date, involving nearly 50,000 patients across three key clinical studies: Librexia STROKE, Librexia ACS, and Librexia AF.
|
|
2.
|
F. Hoffmann-La Roche Ltd
|
Roche focuses on neurological disorders and is actively involved in stroke prevention and treatment through its thrombectomy and antithrombotic therapies. Roche's portfolio includes genetic testing and biomarker-based diagnostic tools that help with early diagnosis and improved treatment for stroke patients.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In July 2023, Roche announced a new partnership with Alnylam to develop and commercialize zilebesir, an investigational RNAi therapy currently in Phase 2 for the treatment of high blood pressure. This collaboration combines Alnylam's proven experience in RNAi therapy with Roche's global commercial reach, commitment to innovation and desire to change the landscape for patients with serious cardiovascular disease.
|
|
3.
|
Boehringer Ingelheim International GmbH
|
Boehringer Ingelheim is well-known in the stroke market for its innovative thrombolytic therapies and anticoagulants. The company’s dabigatran (Pradaxa) is widely used in the prevention and treatment of stroke in atrial fibrillation (AF) patients, providing effective alternatives to traditional anticoagulation therapy.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In February 2025, Boehringer Ingelheim introduced a fast-acting stroke medication in the UAE, significantly reducing treatment administration time for acute ischemic stroke (AIS) patients. The newly approved therapy is administered as a single IV bolus over five to ten seconds, offering a major advancement compared to conventional treatments that typically take an hour.
|
|
4.
|
DAIICHI SANKYO COMPANY, LIMITED
|
Daiichi Sankyo has developed antithrombotic therapies, including edoxaban (Lixiana), used in stroke prevention for patients with atrial fibrillation. Daiichi Sankyo continues to invest in new stroke treatments and is committed to improving patient outcomes with advanced therapeutics in the stroke care field.
|
|
Americas, Asia-Pacific, and Europe
|
In September 2020, Daiichi Sankyo Company Limited announced that it has submitted a supplemental application in Japan for the extended approval of the anticoagulant edoxaban (edoxaban benzoate hydrate) in elderly patients with nonvalvular regurgitation and severe bleeding. Risk.
|
|
5.
|
Sanofi
|
Sanofi’s stroke-related therapies focus on anticoagulation and stroke prevention in atrial fibrillation. Sanofi is also known for its clot-busting drugs and has been involved in advancing post-stroke rehabilitation treatments. The company’s strong commitment to neuroscience and cardiovascular disease management positions it as a significant player in the global stroke market.
|
|
Americas, Middle East and Africa, Asia-Pacific, and Europe
|
In December 2024, the FDA awarded Breakthrough Therapy Designation (BTD) to Sanofi’s tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis (nrSPMS). The designation was granted based on promising findings from the HERCULES Phase III clinical trial, as reported by the company.
|
Conclusion
The global stroke market is set for sustained growth, driven by the rising incidence of stroke and the continuous evolution of diagnostic and treatment solutions. Advancements in technology, particularly in diagnostic imaging and stroke rehabilitation, are improving patient outcomes and recovery times. As the aging population continues to grow and the global burden of stroke rises, the demand for effective treatments and rehabilitation solutions will remain high.
